ImmunoGen stock was rising Thursday following an announcement that biopharmaceutical company AbbVie has agreed to buy the cancer treatment developer for $10.1 billion. Under the terms of the sale agreement, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share. The transaction is subject to shareholder and regulatory approval.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles